1,721,065 research outputs found
Philadelphia chromosome-positive acute lymphoblastic leukemia
Full text linkPhiladelphia chromosome-positive Acute Lymphoblastic Leukemi
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity
No full text"Metodo per la diagnosi e/o il monitoraggio della mucormicosi" - "Method for the diagnosis of and/or monitoring mucormycosis"
No full textA method is described for the diagnosis and/or monitoring of active or previous infection by Mucor which consists in the identification of Mucorales-specific T cells in samples from biological fluids taken from the patient and put into contact with a Mucor antigen. These specific immune responses can be detected by the execution of immunoenzymatic assays (ELISPOT, Quantiferon) or of immunocytofluorimetric assays [Cytokine Secretion Assay (CSA), Intracellular Cytokine Staining (ICS)] in vitro. In greater detail, the method in question provides for checking for the presence of specific IFN-γ producing T cells, of specific IL-10 producing T cells and/or specific IL- 4 producing T cells
How I treat HHV8/KSHV-related diseases in posttransplant patients.
No full textPosttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV)
primary infection and/or reactivations are associated with uncommon and sometimes
fatal, neoplastic, and non-neoplastic diseases. HHV8-related clinical
manifestations notably range from Kaposi sarcoma (KS) to either primary effusion
lymphoma or multicentric Castleman disease B-cell malignancies, and from
polyclonal HHV8-positive plasmacytic lymphoproliferative disorders to bone marrow
failure and peripheral cytopenias, associated or not with hemophagocytic
syndromes, and to acute hepatitis syndromes. We reviewed the patient series
reported in the literature and summarized clinical management aspects, in terms
of diagnosis, follow-up, and treatment. We described typical clinical
presentations and histopathologic diagnostic features of these diseases, and we
discussed the role of HHV8-specific serologic, molecular, and immunologic assays,
particularly focusing on recent data from HHV8-specific T-cell monitoring in
posttransplantation KS patients. We finally discussed actual therapeutic options,
namely, the reduction or discontinuation of immunosuppressive therapy or the
switch from calcineurin inhibitors to mTOR inhibitors, as alternatives to
antineoplastic chemotherapy, along with the use of antiherpesvirus agents as
prophylactic or therapeutic measures, and treatment with rituximab in
posttrans-plantation multicentric Castleman disease patients and non-neoplastic
HHV8-associated syndromes
Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients.
Full text linkPotentially fatal lung toxicity occurs in 12-20% of leukemic patients treated with cytarabine especially at intermediate to high doses, usually presenting as noncardiogenic pulmonary edema (NCPE). Anecdotally the association between cytarabine and the onset of bronchiolitis obliterans organizing pneumonia (BOOP) has been reported. We describe here three cases of patients affected by acute myeloid leukemia (AML) treated with chemotherapeutic regimens including high dose cytarabine, who developed early onset of fever, mild dyspnea, moderate hypoxemia on arterial blood gas analysis and lung infiltrates documented by high-resolution computerized tomography (HRCT), with a more indolent behaviour and a benign clinical outcome, compared with similar cases previously reported in the literature. Our cases widen the spectrum of clinical features of cytarabine-related toxicity in leukemic patients
Splenomegaly in hematological malignancies and portal hypertension
No full textSplenomegaly in hematological malignancies and portal hypertension
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
Full text linkAcute myeloid leukemia (AML) with NPM1 gene mutations is currently recognized as a distinct entity, due to its unique biological and clinical features. We summarize here the results of published studies investigating the clinical application of minimal/measurable residual disease (MRD) in patients with NPM1-mutated AML, receiving either intensive chemotherapy or hematopoietic stem cell transplantation. Several clinical trials have so far demonstrated a significant independent prognostic impact of molecular MRD monitoring in NPM1-mutated AML and, accordingly, the Consensus Document from the European Leukemia Net MRD Working Party has recently recommended that NPM1-mutated AML patients have MRD assessment at informative clinical timepoints during treatment and follow-up. However, several controversies remain, mainly with regard to the most clinically significant timepoints and the MRD thresholds to be considered, but also with respect to the optimal source to be analyzed, namely bone marrow or peripheral blood samples, and the correlation of MRD with other known prognostic indicators. Moreover, we discuss potential advantages, as well as drawbacks, of newer molecular technologies such as digital droplet PCR and next-generation sequencing in comparison to conventional RQ-PCR to quantify NPM1-mutated MRD. In conclusion, further prospective clinical trials are warranted to standardize MRD monitoring strategies and to optimize MRD-guided therapeutic interventions in NPM1-mutated AML patients
Human herpesvirus 6 latency characterized by high viral load: Chromosomal integration in many, but not all, cells
No full textn.d
- …
